Medicine · MapleScholar Plus

Fixing a 90-Year-Old Mistake: Why PCOS is Being Renamed a Metabolic Disease

For nearly a century, medicine treated PCOS as a simple fertility problem caused by ovarian cysts; updated clinical science proves that the condition is a systemic endocrine and insulin disease that happens to affect ovaries. Published in Expert Review of Molecular Diagnostics, this reclassification to Polyendocrine Metabolic Ovarian Syndrome (PMOS) removes medical stigma and reframes care around lifetime cardiovascular health, diabetes prevention, and hormonal balance.

Author
Fernando M. Reis et al.
Published
2026
Journal
Expert Review of Molecular Diagnostics
Last updated
September 2026
Fixing a 90-Year-Old Mistake: Why PCOS is Being Renamed a Metabolic Disease

Millions of women diagnosed with Polycystic Ovary Syndrome (PCOS) are told by doctors that they have dangerous "cysts" on their ovaries that only matter when they want to get pregnant. In reality, these are not cysts at all—they are normal, immature egg follicles that get stuck because of underlying metabolic imbalances.

Endocrinologists and women's health advocates are replacing the misleading name with PMOS: Polyendocrine Metabolic Ovarian Syndrome. The new name highlights that the real engine of the disease is insulin resistance and hormone signaling, which increases the risk of type 2 diabetes, high blood pressure, and cardiovascular disease across a woman's entire lifetime.

Renaming the condition shifts medical care from reactive fertility fixes to proactive lifelong health. By guiding early screening for metabolic disorders, by eliminating patient anxiety over non-existent cysts, and by securing insurance coverage for metabolic treatments like GLP-1 drugs, PMOS terminology modernizes women's healthcare.

Reference

Reis, F. M., Vidigal, I. G. A., Elizarraras, J. L., & Comim, F. V. (2026). What’s in a name: the potential impact of the updated terminology of polyendocrine metabolic ovarian syndrome (PMOS). Expert Review of Molecular Diagnostics, 26(9), 733–737.

Title

What’s in a name: the potential impact of the updated terminology of polyendocrine metabolic ovarian syndrome (PMOS)

Abstract

INTRODUCTION: Polycystic ovary syndrome (PCOS) was recently renamed polyendocrine metabolic ovarian syndrome (PMOS). AREAS COVERED: We review the renaming process, the potential advantages, and the challenges associated with this global effort. A large consortium of experts and patient representatives debated whether renaming was justified, what principles should guide a new name, and how such a change could be implemented without disrupting clinical care, research, education, or patient communication. Surveys indicated that awareness of the broader features of the syndrome improved in the last years after dissemination strategies and patient advocacy initiatives, but important gaps remained, particularly around the risk of comorbidities. EXPERT OPINION: New perspectives emerge with renaming PCOS into PMOS after a carefully planned effort to improve scientific accuracy, patient understanding, and clinical communication while minimizing confusion during implementation. The new terminology emphasizes the syndrome's endocrine and metabolic nature and removes the misleading reference to 'polycystic' ovaries. Similar to previous successful nomenclature updates in gynecology, this gradual transition aims to enhance education, interdisciplinary care, research, and long-term management, ultimately supporting more accurate diagnosis and improved patient outcomes.

Cited 0 times · View on doi.org

Continue

Continue Exploring

Ask this paper your own questions, or keep browsing the verified research catalogue.